{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T20:10:04Z","timestamp":1756325404149,"version":"3.44.0"},"reference-count":17,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,12,16]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>We report using the programmed death-1 immune checkpoint inhibitor (ICI) antibody, nivolumab, as part of a multimodal treatment strategy in small cell bladder carcinoma (SCBC). The patient presented with gross haematuria and was diagnosed with urothelial carcinoma with SCBC. He received neoadjuvant chemotherapy (NAC; carboplatin plus etoposide) according to the small cell lung cancer regimen. After three cycles of NAC, there was no progression of local disease, and a robot-assisted radical cystectomy with ileal conduit was conducted. Post surgery, the patient was treated with nivolumab (240 mg) every 2 weeks as a maintenance therapy after adjuvant cisplatin plus etoposide therapy. After more than 1.5 years post surgery, no tumour recurrence or metastases are present. The patient was treated with nivolumab, which was curative after radical cystectomy. Further research is required to elucidate the potential role of ICIs in SCBC.<\/jats:p>","DOI":"10.1136\/bcr-2023-257402","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T10:35:33Z","timestamp":1703932533000},"page":"e257402","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Small cell bladder carcinoma treated with nivolumab as adjuvant maintenance therapy"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6123-9467","authenticated-orcid":false,"given":"Kosuke","family":"Kitamura","sequence":"first","affiliation":[{"name":"Department of Urology, Juntendo University Nerima Hospital, Nerima-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nonami","sequence":"additional","affiliation":[{"name":"Department of Urology, Juntendo University Nerima Hospital, Nerima-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-5195","authenticated-orcid":false,"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[{"name":"Department of Urology, Juntendo University Nerima Hospital, Nerima-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[{"name":"Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,12,30]]},"reference":[{"key":"2025082712434190000_16.12.e257402.1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"2025082712434190000_16.12.e257402.2","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2490-9-4","article-title":"Outcome of recurrent and metastatic small cell carcinoma of the bladder","volume":"9","author":"Ismaili","year":"2009","journal-title":"BMC Urol"},{"key":"2025082712434190000_16.12.e257402.3","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.euf.2017.09.001","article-title":"Treatment patterns and survival outcomes for patients with small cell carcinoma of the bladder","volume":"4","author":"Fischer-Valuck","year":"2018","journal-title":"Eur Urol Focus"},{"key":"2025082712434190000_16.12.e257402.4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0041"},{"key":"2025082712434190000_16.12.e257402.5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1185\/03007995.2016.1155982","article-title":"Small cell carcinoma of the urinary bladder: changing trends in the current literature","volume":"32","author":"Erdem","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"2025082712434190000_16.12.e257402.6","first-page":"957","article-title":"Adjuvant Nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"385","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"2025082712434190000_16.12.e257402.7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.907454","article-title":"Neoadjuvant and adjuvant chemotherapy for variant histology bladder cancers: A systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"2025082712434190000_16.12.e257402.8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/j.seminoncol.2012.08.009","article-title":"Small cell bladder cancer: biology and management","volume":"39","author":"Fahed","year":"2012","journal-title":"Semin Oncol"},{"key":"2025082712434190000_16.12.e257402.9","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/j.clgc.2016.09.005","article-title":"Small-cell carcinoma of the bladder: 20-year single-institution retrospective review","volume":"15","author":"Jung","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2025082712434190000_16.12.e257402.10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20903"},{"key":"2025082712434190000_16.12.e257402.11","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1002\/cncr.26197","article-title":"A surveillance, epidemiology, and end results analysis of small cell carcinoma of the bladder: epidemiology, Prognostic variables, and treatment trends","volume":"117","author":"Koay","year":"2011","journal-title":"Cancer"},{"key":"2025082712434190000_16.12.e257402.12","first-page":"8","article-title":"Survival analysis of small cell Carcinomas of the Genitourinary system","volume":"36","author":"Baralo","year":"2023","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2025082712434190000_16.12.e257402.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.4905"},{"key":"2025082712434190000_16.12.e257402.14","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"The Lancet"},{"key":"2025082712434190000_16.12.e257402.15","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s11864-022-00989-7","article-title":"Immune Checkpoint inhibitors and Chemoradiation for limited-stage small cell lung cancer","volume":"23","author":"Schlick","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"2025082712434190000_16.12.e257402.16","doi-asserted-by":"crossref","first-page":"2532518","DOI":"10.1155\/2019\/2532518","article-title":"Immune exclusion is frequent in small-cell carcinoma of the bladder","volume":"2019","author":"Mandelkow","year":"2019","journal-title":"Dis Markers"},{"key":"2025082712434190000_16.12.e257402.17","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and Ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: Checkmate 451","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-257402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:43:49Z","timestamp":1756323829000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-257402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,30]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/bcr-2023-257402"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-257402","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}